111 related articles for article (PubMed ID: 14555216)
1. Slowly getting a clue on CD95 ligand biology.
Linkermann A; Qian J; Janssen O
Biochem Pharmacol; 2003 Oct; 66(8):1417-26. PubMed ID: 14555216
[TBL] [Abstract][Full Text] [Related]
2. CD95 ligand--death factor and costimulatory molecule?
Janssen O; Qian J; Linkermann A; Kabelitz D
Cell Death Differ; 2003 Nov; 10(11):1215-25. PubMed ID: 12894217
[TBL] [Abstract][Full Text] [Related]
3. Insights into the molecular regulation of FasL (CD178) biology.
Lettau M; Paulsen M; Schmidt H; Janssen O
Eur J Cell Biol; 2011; 90(6-7):456-66. PubMed ID: 21126798
[TBL] [Abstract][Full Text] [Related]
4. Multiple interactions of the cytosolic polyproline region of the CD95 ligand: hints for the reverse signal transduction capacity of a death factor.
Wenzel J; Sanzenbacher R; Ghadimi M; Lewitzky M; Zhou Q; Kaplan DR; Kabelitz D; Feller SM; Janssen O
FEBS Lett; 2001 Dec; 509(2):255-62. PubMed ID: 11741599
[TBL] [Abstract][Full Text] [Related]
5. Identification of interaction partners of the cytosolic polyproline region of CD95 ligand (CD178).
Ghadimi MP; Sanzenbacher R; Thiede B; Wenzel J; Jing Q; Plomann M; Borkhardt A; Kabelitz D; Janssen O
FEBS Lett; 2002 May; 519(1-3):50-8. PubMed ID: 12023017
[TBL] [Abstract][Full Text] [Related]
6. Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes.
Cippitelli M; Fionda C; Di Bona D; Di Rosa F; Lupo A; Piccoli M; Frati L; Santoni A
J Immunol; 2002 Feb; 168(3):1154-66. PubMed ID: 11801650
[TBL] [Abstract][Full Text] [Related]
7. Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection.
Cossarizza A; Stent G; Mussini C; Paganelli R; Borghi V; Nuzzo C; Pinti M; Pedrazzi J; Benatti F; Esposito R; Røsok B; Nagata S; Vella S; Franceschi C; De Rienzo B
AIDS; 2000 Mar; 14(4):345-55. PubMed ID: 10770536
[TBL] [Abstract][Full Text] [Related]
8. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.
Behrens CK; Igney FH; Arnold B; Möller P; Krammer PH
J Immunol; 2001 Mar; 166(5):3240-7. PubMed ID: 11207278
[TBL] [Abstract][Full Text] [Related]
9. A regulatory element in the CD95 (APO-1/Fas) ligand promoter is essential for responsiveness to TCR-mediated activation.
Li-Weber M; Laur O; Hekele A; Coy J; Walczak H; Krammer PH
Eur J Immunol; 1998 Aug; 28(8):2373-83. PubMed ID: 9710215
[TBL] [Abstract][Full Text] [Related]
10. CD95 ligand expression as a mechanism of immune escape in breast cancer.
Müschen M; Moers C; Warskulat U; Even J; Niederacher D; Beckmann MW
Immunology; 2000 Jan; 99(1):69-77. PubMed ID: 10651943
[TBL] [Abstract][Full Text] [Related]
11. T cell activation-induced and HIV tat-enhanced CD95(APO-1/Fas) ligand transcription involves NF-kappaB.
Li-Weber M; Laur O; Dern K; Krammer PH
Eur J Immunol; 2000 Feb; 30(2):661-70. PubMed ID: 10671224
[TBL] [Abstract][Full Text] [Related]
12. CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo.
Igney FH; Behrens CK; Krammer PH
Int J Cancer; 2005 Jan; 113(1):78-87. PubMed ID: 15386427
[TBL] [Abstract][Full Text] [Related]
13. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo.
Ehl S; Hoffmann-Rohrer U; Nagata S; Hengartner H; Zinkernagel R
J Immunol; 1996 Apr; 156(7):2357-60. PubMed ID: 8786290
[TBL] [Abstract][Full Text] [Related]
14. TRAIL/Apo-2-ligand-induced apoptosis in human T cells.
Jeremias I; Herr I; Boehler T; Debatin KM
Eur J Immunol; 1998 Jan; 28(1):143-52. PubMed ID: 9485194
[TBL] [Abstract][Full Text] [Related]
15. The regulation of CD95 (Fas) ligand expression in primary T cells: induction of promoter activation in CD95LP-Luc transgenic mice.
Norian LA; Latinis KM; Eliason SL; Lyson K; Yang C; Ratliff T; Koretzky GA
J Immunol; 2000 May; 164(9):4471-80. PubMed ID: 10779747
[TBL] [Abstract][Full Text] [Related]
16. Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation.
Lu L; Qian S; Hershberger PA; Rudert WA; Lynch DH; Thomson AW
J Immunol; 1997 Jun; 158(12):5676-84. PubMed ID: 9190916
[TBL] [Abstract][Full Text] [Related]
17. Foxp3-mediated suppression of CD95L expression confers resistance to activation-induced cell death in regulatory T cells.
Weiss EM; Schmidt A; Vobis D; Garbi N; Lahl K; Mayer CT; Sparwasser T; Ludwig A; Suri-Payer E; Oberle N; Krammer PH
J Immunol; 2011 Aug; 187(4):1684-91. PubMed ID: 21746966
[TBL] [Abstract][Full Text] [Related]
18. Stromal derived factor-1 alpha (SDF-1 alpha) induces CD4+ T cell apoptosis via the functional up-regulation of the Fas (CD95)/Fas ligand (CD95L) pathway.
Colamussi ML; Secchiero P; Gonelli A; Marchisio M; Zauli G; Capitani S
J Leukoc Biol; 2001 Feb; 69(2):263-70. PubMed ID: 11272277
[TBL] [Abstract][Full Text] [Related]
19. The influence of CD95L expression on tumor rejection in mice.
Igney FH; Behrens CK; Krammer PH
Eur J Immunol; 2003 Oct; 33(10):2811-21. PubMed ID: 14515265
[TBL] [Abstract][Full Text] [Related]
20. Quantitation of CD95 and CD95L mRNA expression in chronic and acute HIV-1 infection by competitive RT-PCR.
Pinti M; Nasi M; Moretti L; Mussini C; Petrusca D; Esposito R; Cossarizza A
Ann N Y Acad Sci; 2000; 926():46-51. PubMed ID: 11193040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
